A study including 67 patients with renal cell cancer found that antibiotic use before or after anti-PD-2/PD-L1 immunotherapy resulted in significantly shorter progression-free survival and overall survival [78]. The gene discussed is PAF1; the disease is renal cell adenocarcinoma.